Xenon Financial Statements From 2010 to 2026

XENE Stock

USD 41.22 0.90 2.14%

Xenon Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Xenon Pharmaceuticals' valuation are provided below:

Gross Profit

-265.2 M

Market Capitalization

3.2 B

Enterprise Value Revenue

361.6021

Revenue

7.5 M

Earnings Share

(3.89)

There are over one hundred nineteen available fundamental gauges for Xenon Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Xenon Pharmaceuticals' prevalent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2.9 B. The current year's Enterprise Value is expected to grow to about 2.8 B

Xenon Pharmaceuticals Total Revenue

9.43 Million

Check Xenon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 6.7 M or Selling General Administrative of 83.2 M, as well as many indicators such as Price To Sales Ratio of 239, Dividend Yield of 0.0 or PTB Ratio of 2.16. Xenon financial statements analysis is a perfect complement when working with Xenon Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Xenon Stock

Check out the analysis of Xenon Pharmaceuticals Correlation against competitors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

Xenon Pharmaceuticals Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Common Stock Shares Outstanding

94.1 M

89.6 M

34.6 M

Slightly volatile

Total Assets

963.8 M

917.9 M

349.4 M

Slightly volatile

Short and Long Term Debt Total

10 M

10.4 M

7.8 M

Slightly volatile

Other Current Liabilities

28.3 M

27 M

8.9 M

Slightly volatile

Total Current Liabilities

43 M

40.9 M

20.4 M

Slightly volatile

Total Stockholder Equity

911.5 M

868.1 M

317.4 M

Slightly volatile

Other Liabilities

606.2 K

638.1 K

6.4 M

Slightly volatile

Property Plant And Equipment Net

22 M

20.9 M

8 M

Slightly volatile

Accounts Payable

3.2 M

5.8 M

2.8 M

Slightly volatile

Cash

172.3 M

164.1 M

81.5 M

Slightly volatile

Non Current Assets Total

196.7 M

187.3 M

62.7 M

Slightly volatile

Cash And Short Term Investments

757 M

720.9 M

282.6 M

Slightly volatile

Net Receivables

929.5 K

1.7 M

846.3 K

Slightly volatile

Common Stock Total Equity

1.3 B

1.2 B

477.3 M

Slightly volatile

Liabilities And Stockholders Equity

963.8 M

917.9 M

349.4 M

Slightly volatile

Non Current Liabilities Total

7.1 M

6.9 M

11.3 M

Slightly volatile

Other Current Assets

8.3 M

7.9 M

3.2 M

Slightly volatile

Total Liabilities

28.8 M

49.7 M

30.6 M

Very volatile

Property Plant And Equipment Gross

19.5 M

36.4 M

17 M

Slightly volatile

Total Current Assets

767.1 M

730.6 M

286.7 M

Slightly volatile

Common Stock

1.8 B

1.7 B

576.5 M

Slightly volatile

Property Plant Equipment

7.8 M

7.5 M

3.7 M

Slightly volatile

Capital Surpluse

171.6 M

163.4 M

74.9 M

Slightly volatile

Long Term Debt Total

11.7 M

12.5 M

9 M

Slightly volatile

Net Invested Capital

462.5 M

868.1 M

293.7 M

Slightly volatile

Short and Long Term Debt

2.9 M

5.3 M

2.7 M

Slightly volatile

Net Working Capital

380.4 M

689.6 M

242.4 M

Slightly volatile

Short Term Debt

2.5 M

1.2 M

1.9 M

Very volatile

Capital Stock

900.5 M

1.7 B

617.4 M

Slightly volatile

Capital Lease Obligations

7.9 M

10.4 M

4.1 M

Slightly volatile

Deferred Long Term Asset Charges

190.4 K

214.2 K

233.8 K

Slightly volatile

Xenon Pharmaceuticals Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

3.1 M

2.9 M

1.4 M

Slightly volatile

Selling General Administrative

83.2 M

79.2 M

24.7 M

Slightly volatile

Other Operating Expenses

337.3 M

321.2 M

100.8 M

Slightly volatile

Research Development

254.1 M

242 M

75.8 M

Slightly volatile

Total Operating Expenses

334.2 M

318.2 M

90.1 M

Slightly volatile

Cost Of Revenue

2.8 M

2.9 M

30.3 M

Slightly volatile

Interest Income

50.6 M

48.2 M

12.9 M

Slightly volatile

Reconciled Depreciation

3.1 M

2.9 M

1.2 M

Slightly volatile

Selling And Marketing Expenses

2.8 M

3.2 M

3.5 M

Slightly volatile

Xenon Pharmaceuticals Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

61.2 M

58.3 M

15 M

Slightly volatile

Begin Period Cash Flow

179.5 M

170.9 M

69.3 M

Slightly volatile

Depreciation

3.1 M

2.9 M

1.4 M

Slightly volatile

Capital Expenditures

3.7 M

3.5 M

1.7 M

Slightly volatile

End Period Cash Flow

172.3 M

164.1 M

76 M

Slightly volatile

Sale Purchase Of Stock

770.2 K

810.8 K

17.9 M

Very volatile

Issuance Of Capital Stock

10.3 M

10.9 M

108.4 M

Very volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

239

228

98.316

Slightly volatile

PTB Ratio

2.16

3.64

2.5379

Slightly volatile

Days Sales Outstanding

64.67

34.33

56.7021

Very volatile

Book Value Per Share

5.52

8.72

7.2293

Pretty Stable

Stock Based Compensation To Revenue

2.04

1.94

1.2278

Slightly volatile

Capex To Depreciation

1.1

1.08

1.2751

Slightly volatile

PB Ratio

2.16

3.64

2.5379

Slightly volatile

Payables Turnover

0.43

0.45

10.0833

Pretty Stable

Sales General And Administrative To Revenue

2.65

3.13

3.0415

Pretty Stable

Research And Ddevelopement To Revenue

8.74

10.09

9.9326

Pretty Stable

Capex To Revenue

0.14

0.28

0.1929

Slightly volatile

Cash Per Share

10.49

9.26

13.7785

Slightly volatile

Days Payables Outstanding

683

651

178

Slightly volatile

Current Ratio

13.26

16.06

14.7718

Slightly volatile

Tangible Book Value Per Share

5.52

8.72

7.2293

Pretty Stable

Receivables Turnover

10.45

11.0

26.7104

Slightly volatile

Shareholders Equity Per Share

5.52

8.72

7.2293

Pretty Stable

Debt To Equity

0.013

0.0137

0.1039

Slightly volatile

Capex Per Share

0.0431

0.0454

0.0876

Slightly volatile

Graham Net Net

4.62

6.76

5.9566

Pretty Stable

Revenue Per Share

0.17

0.18

1.7728

Slightly volatile

Interest Debt Per Share

0.13

0.1157

0.4722

Slightly volatile

Debt To Assets

0.0123

0.013

0.0673

Slightly volatile

Graham Number

7.77

9.47

9.913

Pretty Stable

Price Book Value Ratio

2.16

3.64

2.5379

Slightly volatile

Days Of Payables Outstanding

683

651

178

Slightly volatile

Ebt Per Ebit

1.17

0.98

1.0554

Slightly volatile

Company Equity Multiplier

1.68

1.22

1.9335

Slightly volatile

Long Term Debt To Capitalization

0.13

0.12

0.1228

Slightly volatile

Total Debt To Capitalization

0.0129

0.0136

0.0895

Slightly volatile

Debt Equity Ratio

0.013

0.0137

0.1039

Slightly volatile

Quick Ratio

13.29

16.06

14.8013

Slightly volatile

Net Income Per E B T

1.1

1.13

1.0116

Slightly volatile

Cash Ratio

7.24

4.61

6.0973

Very volatile

Days Of Sales Outstanding

64.67

34.33

56.7021

Very volatile

Price To Book Ratio

2.16

3.64

2.5379

Slightly volatile

Fixed Asset Turnover

0.61

0.64

3.8976

Slightly volatile

Debt Ratio

0.0123

0.013

0.0673

Slightly volatile

Price Sales Ratio

239

228

98.316

Slightly volatile

Asset Turnover

0.0137

0.0144

0.126

Slightly volatile

Price Fair Value

2.16

3.64

2.5379

Slightly volatile

Xenon Pharmaceuticals Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

2.9 B

2.7 B

1 B

Slightly volatile

Xenon Fundamental Market Drivers

Xenon Upcoming Events

	6th of March 2024 Upcoming Quarterly Report	View
	14th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	6th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Xenon Pharmaceuticals Financial Statements

Xenon Pharmaceuticals stakeholders use historical fundamental indicators, such as Xenon Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Xenon Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xenon Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Xenon Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xenon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	8.4 M	7.2 M
Cost Of Revenue	2.9 M	2.8 M
Stock Based Compensation To Revenue	1.94	2.04
Sales General And Administrative To Revenue	3.13	2.65
Research And Ddevelopement To Revenue	10.09	8.74
Capex To Revenue	0.28	0.14
Revenue Per Share	0.18	0.17
Ebit Per Revenue	(15.74)	(16.53)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

JBL	Jabil Circuit
MRK	Merck Company
AMGN	Amgen Inc

When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:

How To Invest In Xenon

Details

Is Xenon Stock a good investment?

Details

What is Xenon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Xenon Pharmaceuticals Correlation against competitors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.89)

Revenue Per Share

0.095

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.30)

Return On Equity

(0.45)

The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Xenon Financial Statements From 2010 to 2026

Xenon Pharmaceuticals Total Revenue

9.43 Million

Xenon Pharmaceuticals Balance Sheet

Xenon Pharmaceuticals Income Statement

Xenon Pharmaceuticals Cash Flow Statement

Financial Ratios

Xenon Pharmaceuticals Valuation Data

Xenon Fundamental Market Drivers

Xenon Upcoming Events

About Xenon Pharmaceuticals Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY